| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 1397671 | European Journal of Medicinal Chemistry | 2010 | 9 Pages |
In an effort to discover new and effective chemotherapeutic agents from this laboratory for the treatment of tuberculosis, here in we describe the synthesis and biological evaluation of a series of novel benzothiadiazine 1,1-dioxide (BTD) based congeners by using rifampicin, streptomycin; ciprofloxacin and amphotericin as positive controls. Further, to understand structural requirements for exploring the structure activity relationship of BTDs, cytotoxicity and in vivo study of recently reported potent molecule 4 (MIC = 1 μg/mL) is also discussed.
Graphical abstractA new series of benzothiadiazine 1,1-dioxide based congeners was synthesized and evaluated against Mycobacterium tuberculosis, Gram-positive, Gram-negative bacteria and fungi. Further, in vivo activity of earlier potent molecule of this series is also discussed.Figure optionsDownload full-size imageDownload as PowerPoint slide
